Suven Pharma - Strong Overall Q4 Results Led By Pharma CRAMS: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Suven Pharmaceuticals Ltd.'s Q4 FY21 revenue grew 40.3% YoY to Rs 259 crore amid 51.3% YoY growth in pharma contract research and manufacturing services sales to Rs 137.7 crore.
Specialty chemical CRAMS also posted robust growth of 35.1% YoY to Rs 109 crore.
However, formulation sales fell 36% YoY to Rs 12.1 crore.
Ebitda margins declined 566 basis points YoY to 36.2% mainly due to lower gross margin performance (down 658 basis points YoY at 64.7%).
Subsequently, Ebitda grew 21.3% YoY to Rs 94 crore.
Profit after tax was up 12% YoY to Rs 83 crore.
Delta vis-a-vis Ebitda was due to higher tax rate and lower profit share from associates.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.